Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. - Wikidata - awgldk - TriplyDB

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.

http://www.wikidata.org/entity/Q34027512

about

Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease.Lessons from ONTARGET.Recent changes in the landscape of combination RAS blockade.Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue.Outpatient management of chronic heart failure.Perindopril arginine + amlodipine for the treatment of hypertension in the USA.

P2860

Q34124779-88C81A5F-0FFF-431A-974B-BC0177C48831 Q34200885-0DC26284-55B4-4FC9-8617-576F890DE011 Q34849485-49E2B62A-5865-4147-A182-8C3833EC6F3A Q35154540-72C499B7-70EF-4D8F-B7C0-4C16B0B24523 Q36480076-12A2C22C-EA61-4697-856A-0C406B00BBA4 Q36867310-2E94F94C-E273-4B08-A37B-16DADDD09B57 Q36975699-6E55D195-3A6E-425E-92D2-228A514931C4 Q37247749-248FF09E-BF89-481F-97F0-9D64F7108331 Q37629835-61B6AF9D-128F-461F-A441-60CDE3D46510 Q38859432-DB5B8670-EF0F-42C0-954B-734EAA88D09C Q48080337-7EF049CE-25D8-43A9-B61A-BE38FF0994F9 Q50998627-E5B3C7A3-50AB-4FEB-88DB-3AF4D46240DB Q53674965-77FC87AB-89B6-4FE0-B118-B10077DCB5C9

P2860

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.

http://www.wikidata.org/entity/Q34027512

description

2000 nî lūn-bûn

@nan

2000 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Therapeutic implications of es ...... ts with chronic heart failure.

@ast

Therapeutic implications of es ...... ts with chronic heart failure.

@en

Therapeutic implications of es ...... ts with chronic heart failure.

@nl

type

label

Therapeutic implications of es ...... ts with chronic heart failure.

@ast

Therapeutic implications of es ...... ts with chronic heart failure.

@en

Therapeutic implications of es ...... ts with chronic heart failure.

@nl

prefLabel

Therapeutic implications of es ...... ts with chronic heart failure.

@ast

Therapeutic implications of es ...... ts with chronic heart failure.

@en

Therapeutic implications of es ...... ts with chronic heart failure.

@nl

P1433

Q34027512-3CF55121-91EA-4F38-8076-9BFFAD20A0F8

P1476

Q34027512-4F5C9BA5-728C-4714-9455-CC38873432FF

P2093

Q34027512-821185DB-C757-42CA-9EA1-CC630CA05BEE

Q34027512-8DF23179-1C33-4CFD-9293-5297DADC4DE3

Q34027512-99A60BA9-8973-40CA-AE36-E89AEC81B6CF

Q34027512-B2322705-5DD6-4A38-9F25-05AF49425FA4

P2860

Q34027512-3662F299-004E-4A0F-870E-D1F640278B4D

Q34027512-4E040239-AB08-461C-97A5-EFC91A81FB4F

Q34027512-5F7A65BC-E358-4024-B5E0-2547FA8FDF40

Q34027512-8AA24E6E-D400-4AB7-80C1-DA4764500D46

Q34027512-B5C04E21-99F5-439E-B5E4-98EA58B16BB4

Q34027512-DA50596A-AEEA-43D8-84E5-483017FEEF00

Q34027512-EA2885A3-6B93-4103-A0D1-51AFAB748EFF

Q34027512-FA5A93A1-3044-478E-BE72-2BF88420B336

P2888

Q34027512-697B4C38-5235-4375-8D11-6D1F68DBE543

P304

Q34027512-86E03EA5-B9CA-40CA-8802-9B7417C1D975

P31

Q34027512-221637DC-EDF6-418A-9D44-B83620151A8E

P356

Q34027512-552A8E13-A224-45B9-966D-D6304EA2041A

P433

Q34027512-E349C7B9-ECDC-44EC-941E-635C64090668

P478

Q34027512-916AA18C-8473-49E5-BA4E-140FC2F18184

P577

Q34027512-C5808F4A-6FC3-47B7-8D06-2BB46D0EF78B

P6179

Q34027512-C4C75B28-601B-4994-AF49-0B939AAD03BE

P698

Q34027512-82E61ED3-EA33-4011-97A8-CA5C38636B0F

P356

S11886-000-0077-3

P1433

Current cardiology reports

P1476

Therapeutic implications of es ...... ts with chronic heart failure.

@en

P2093

E H Sonnenblick

http://www.w3.org/2001/XMLSchema#string

M Berlowitz

http://www.w3.org/2001/XMLSchema#string

P V Ennezat

http://www.w3.org/2001/XMLSchema#string

T H Le Jemtel

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.

Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition.

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

P2888

s11886-000-0077-3

P304

258-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-000-0077-3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2000-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045737456

http://www.w3.org/2001/XMLSchema#string

P698

10980901

http://www.w3.org/2001/XMLSchema#string